Taking the targeted drug Furaquintinib can generally relieve cancer pain to a certain extent. Furaquintinib is suitable for the treatment of patients with metastatic rectal cancer, which mainly reduces and inhibits tumor formation by inhibiting the proliferation as well as metastasis of vascular endothelial cells in the patient’s body. Generally speaking, targeted drugs also have the efficacy of relieving cancer pain in the therapeutic effect of anti-tumor growth. However, it should be noted that furaquintinib may cause adverse reactions such as high blood pressure, proteinuria, skin reactions in the hands and feet, and vocal difficulties. This medication may increase the risk of bleeding and is therefore contraindicated in patients with severe active bleeding, active peptic ulcers, unhealed gastrointestinal perforations, and gastrointestinal fistulas. Furaquintinib needs to be applied reasonably under the guidance of a doctor, and should not be taken blindly without authorization. If serious discomfort occurs after taking it, it is recommended to consult a doctor promptly.